AstraZeneca’s experimental cholesterol drug has shown promising results, significantly reducing low-density lipoprotein (LDL) cholesterol levels by 50.7% when combined with statins. This development has boosted hopes for a potential blockbuster medication that could be part of a combination medicine targeting weight loss and related health issues. The once-daily pill reduces the risk factor associated with strokes and heart attacks, which are often linked to high levels of LDL cholesterol.
Source: https://www.bloomberg.com/news/articles/2025-03-31/astrazeneca-s-potential-blockbuster-pill-halves-high-cholesterol